Sporotrichosis medical therapy

Sporotrichosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Sporotrichosis from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
Treatment
Medical Therapy
Surgery
Prevention
Case Studies
Case #1
Sporotrichosis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Sporotrichosis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Sporotrichosis medical therapy
CDC on Sporotrichosis medical therapy
Sporotrichosis medical therapy in the news
Blogs on Sporotrichosis medical therapy
Directions to Hospitals Treating Sporotrichosis
Risk calculators and risk factors for Sporotrichosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alison Leibowitz [2]

Treatment

Form	Primary Line of Treatment	Alternative Treatment	Remarks/Other
Uncomplicated cutaneous	Itraconazole [200 mg/day]	Itraconazole [200 b.i.d.], terbinafine [500 b.i.d.], SSKI [increasing doses], fluconazole [400-800 mg/day], or local hyperthermia	Continue treatment for 2-4 weeks after lesions resolve.
Osteoarticular	Itraconazole [200 mg b.i.d.]	Limposomal amphotericin B [3-5 mg/kg/day] or deoxycholate amphotericin B [0.7-1 mg/kg/day] until symptom resolution	For a total of 12 months, switch to itraconazole after resolution/end of treatment.
Pulmonary
Meningeal
Dissimated
Sporotrichosis in pregnant women
Sporotrichosis in Children